The PennZone

  • Home
  • Non-profit
  • Music
  • Marketing
  • Books
  • Entertainment
  • Health
  • Automotive
  • Sports

Large Study Analyzes Two Different Classes of ADHD Drugs in Preschool-Age Children
The PennZone/10124083

Trending...
  • SMACK Fighting Championships Announces Influencer Fight Night at Harrah's Philadelphia
  • Pregis Launches Sharp InfinX: On-Demand Rightsized Mailing System Delivering a Precision-Sized Mailer for Every Order
  • After 35 Years, Christian Radio Host Marina Maria Publishes the Novel She Never Forgot
PHILADELPHIA, May 4, 2021 /PRNewswire/ -- In a multi-institutional study, researchers in the Developmental-Behavioral Pediatrics Research Network (DBPNet), led by Children's Hospital of Philadelphia (CHOP), have conducted the first and largest analysis to date comparing the effectiveness and side effects of stimulants like methylphenidate (Ritalin) and alpha-adrenergic agonists like guanfacine (Tenex) in preschool-age children. The researchers found that both classes of drugs have benefits, with differing side effects, suggesting that decisions on which class of drugs to prescribe should be made based on individual patient factors. The retrospective study was published today in JAMA.

"This is really the first study of any size to report on the frequency of improvement and side effects of drugs like guanfacine in preschool-age children," said senior author Nathan J. Blum, MD, Chief of the Division of Developmental and Behavioral Pediatrics at CHOP. "While this study confirms that clinicians are using drugs like guanfacine in preschoolers and that those drugs may be useful in some children, the research also strongly suggests we need future research to look in a rigorous way at the use of alpha-adrenergic agonists in this age group."

More on The PennZone
  • Industrial & systems engineering educator and professional to lead global strategic partnerships for professional society
  • Convergence of AI, Wearable Technology, Remote Patient Monitoring and Real-World Healthcare: PomDoctor Ltd. (N A S D A Q: POM)
  • Timbrana — Construction Project Awareness Software for General Contractors
  • Service Guys Urges Ontario Homeowners to Book Chimney Cleaning and WETT Inspections Before the 2026 Heating Season
  • WOWX Completes Its Transition from CEX to Decentralized Derivatives Infrastructure

To assess the use, effectiveness, and side effects of stimulants and alpha-adrenergic agonists in preschoolers, the researchers reviewed electronic health records of 497 children seen at seven DBPNet outpatient developmental-behavioral pediatric practices between January 2013 and July 2017. Children included in the study were under the age of 6 when first treated with an alpha-adrenergic agonist or stimulant.

The researchers found that 175 children (35%) were prescribed an alpha-adrenergic agonist like guanfacine, while 322 children (65%) were prescribed a stimulant like methylphenidate (Ritalin). Although both groups reported improvement in symptoms, the benefit was slightly larger among those prescribed stimulants (78% vs. 66%).

However, in terms of side effects, patients taking alpha-adrenergic agonists reported fewer side effects than those taking stimulants, with lower rates of moodiness/irritability (50% vs. 29%), appetite suppression (38% vs. 7%), and difficulty sleeping (21% vs. 11%). The only side effect that was more common for those taking alpha-adrenergic agonists than those taking stimulants was daytime sleepiness (38% vs. 3%).

The researchers also found children younger than 4 years old who were prescribed a drug like guanfacine were likely to continue using the medication for longer than if they were prescribed a stimulant. In contrast, children aged 5 to younger than 6 prescribed were likely to continue using the medication for longer if they were prescribed a stimulant. For those ages 4 to 5, there was no significant difference between medications.

"Although the retrospective nature of our study means we weren't able to tell why patients stopped a given medication rather than continued with it, these data support potentially tailoring medication based on a child's age, among other personal factors that might influence medication decisions," Blum said. "Future research should seek to learn more about the use of these classes of drugs in preschool-age children so that we can prescribe the most effective therapy for each patient."

More on The PennZone
  • HSS Medical Supply Celebrates One-Year Anniversary of Its Top Performing Sales Team
  • Jacombs Tickets Partners with UEFA to Offer Champions League Tickets
  • Corner Property Management Awarded Management Contract with Clock Towers Condominium Association
  • WebDrafter Welcomes Honey in the Hollow as a New Marketing Client
  • Geospatial Innovation Comes to Sacramento: FOSS4G NA 2026

Other institutions involved in the study include Boston Children's Hospital; the Perelman School of Medicine at University of Pennsylvania; University of Oklahoma Health Sciences Center; Keck School of Medicine at University of Southern California, Los Angeles; Children's Hospital Los Angeles; Children's Hospital Colorado; Medical University of South Carolina; Stanford University; and Atrium Health.

Harstad et al. "α2-Adrenergic Agonists or Stimulants for Preschool-Age Children With Attention-Deficit/Hyperactivity Disorder," JAMA, online May 4, 2021, DOI: 10.1001/jama.2021.6118

About Children's Hospital of Philadelphia: Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals, and pioneering major research initiatives, Children's Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country. In addition, its unique family-centered care and public service programs have brought the 595-bed hospital recognition as a leading advocate for children and adolescents. For more information, visit http://www.chop.edu

Contact: Camillia Travia
Children's Hospital of Philadelphia
(425) 492-5007
[email protected]

SOURCE Children's Hospital of Philadelphia

Related Links

http://www.chop.edu
Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • After 35 Years, Christian Radio Host Marina Maria Publishes the Novel She Never Forgot
  • Freight Broker 911 CEO and President Milton Collier Is Rebuilding the Path Into Freight Brokerage
  • Boston Industrial Solutions Launches New and Improved Siliart Website for Silicone Decorators
  • TrueNorth to Participate in 2026 Adams County Giving Spree
  • Roots for Boots Announces Rations for the Ranks to Replace MilitaryShare Beginning November 10
  • Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Phoenix
  • SMACK Fighting Championships Announces Influencer Fight Night at Harrah's Philadelphia
  • BetQL Brings Data Driven 5 Star Betting Insights to the Everyday Sports Bettor
  • Sky Quarry's Big Turning Point: CEO Marcus Laun Outlines the Next Phase for N A S D A Q: SKYQ
  • Hunter Is Releasing New Music For The Holidays!
  • Tixpool.com - Naija Premier Event Reseller
  • Work 365 Expands Distributor Integrations with Companial for Microsoft Partners
  • ClassicCarJobs.us Launches Automotive Career Marketplace for Specialty Shops
  • Guardian Data Opens 42,000-Square-Foot Moonachie Facility, Doubling New Jersey Capacity
  • Dutch Mill Bulbs Launches Pink Ribbon Tulip Fundraise ~ National Breast Cancer Foundation, Inc.®
  • SecureMaine 2026 is Here -- Thursday October 8th!
  • Bluestone Laundromat Makes a Difference in the Archbald Community
  • HW Foundation Opens Nominations for Inaugural 50 Under 50 in AI; Deadline Oct. 16
  • Pavillon 30 Years of Addiction Recovery in Western North Carolina, Earns National Accreditation
  • ResC4EU Final Event at KOMPOZYT-EXPO 2026 – Building Resilient European Supply Chains

Popular on PennZone

  • Dion Abadi Publishes Free Collector Tips Hub for Art and Jewelry Buyers
  • Garage door installation or repair in Minnesota? Which makes more sense for your family?
  • UVIFY Brings Advanced Autonomous Systems Research to IROS 2026 in Pittsburgh
  • Spearmint Publishes Full Design of Its Mining Pool Before Building It, Including Legal Drafts
  • Subject matter experts: Present your ideas at IISE Annual Conference 2027 in Louisville
  • Her Song Lives On: Remembering Mrs. Darlene Davis Porter
  • Can Government Operate Better Through Innovation?
  • Most Indiana Plane Crashes Happen Away from the State's Major Airports
  • New Metallized PE Film from Pregis Brings Recyclability to High-Barrier Food Packaging at Pack Expo International in Chicago
  • Put Your Herd on Your Phone: Kiko Nation Makes Livestock Management Simple

Similar on PennZone

  • Constantine "Costa" Kapothanasis II Acquires The Lubri-Loy Company, Carrying a 77-Year-Old American Lubricant Brand Into Its Next Era
  • JFAB Consulting to Celebrate New Brand with Private VIP Event at Acrisure Stadium
  • Industrial & systems engineering educator and professional to lead global strategic partnerships for professional society
  • Convergence of AI, Wearable Technology, Remote Patient Monitoring and Real-World Healthcare: PomDoctor Ltd. (N A S D A Q: POM)
  • HSS Medical Supply Celebrates One-Year Anniversary of Its Top Performing Sales Team
  • RAS AP Consulting Issues National Compliance Alert and Launches Q4 2026 AP Readiness Program Ahead of IRS FIRE → IRIS Cutover
  • Claude Zdanow named Managing Director in Miami, Florida
  • Pregis Launches Sharp InfinX: On-Demand Rightsized Mailing System Delivering a Precision-Sized Mailer for Every Order
  • Freight Broker 911 CEO and President Milton Collier Is Rebuilding the Path Into Freight Brokerage
  • Scoop Social Co. Brings Its Signature Mobile Dessert Experience to Phoenix
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us